ES2656712T3 - Novedoso compuesto sustituido con quinolina - Google Patents
Novedoso compuesto sustituido con quinolina Download PDFInfo
- Publication number
- ES2656712T3 ES2656712T3 ES14837210.5T ES14837210T ES2656712T3 ES 2656712 T3 ES2656712 T3 ES 2656712T3 ES 14837210 T ES14837210 T ES 14837210T ES 2656712 T3 ES2656712 T3 ES 2656712T3
- Authority
- ES
- Spain
- Prior art keywords
- formula
- compound
- group
- amino
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013172746 | 2013-08-22 | ||
| JP2013172746 | 2013-08-22 | ||
| PCT/JP2014/071951 WO2015025936A1 (ja) | 2013-08-22 | 2014-08-22 | 新規キノリン置換化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2656712T3 true ES2656712T3 (es) | 2018-02-28 |
Family
ID=52483707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14837210.5T Active ES2656712T3 (es) | 2013-08-22 | 2014-08-22 | Novedoso compuesto sustituido con quinolina |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9650386B2 (enExample) |
| EP (1) | EP3037424B1 (enExample) |
| JP (1) | JP6161705B2 (enExample) |
| KR (1) | KR101906688B1 (enExample) |
| CN (1) | CN105683195B (enExample) |
| AU (1) | AU2014309788B2 (enExample) |
| BR (1) | BR112016003247B1 (enExample) |
| CA (1) | CA2922077C (enExample) |
| DK (1) | DK3037424T3 (enExample) |
| ES (1) | ES2656712T3 (enExample) |
| HU (1) | HUE034807T2 (enExample) |
| MX (1) | MX370808B (enExample) |
| MY (1) | MY182891A (enExample) |
| NO (1) | NO3037424T3 (enExample) |
| PH (1) | PH12016500225A1 (enExample) |
| PL (1) | PL3037424T3 (enExample) |
| PT (1) | PT3037424T (enExample) |
| RU (1) | RU2689158C2 (enExample) |
| SG (1) | SG11201600759XA (enExample) |
| TW (1) | TWI603971B (enExample) |
| WO (1) | WO2015025936A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI603971B (zh) * | 2013-08-22 | 2017-11-01 | Taiho Pharmaceutical Co Ltd | Novel quinoline substituted compounds |
| JOP20190073A1 (ar) * | 2016-10-31 | 2019-04-07 | Taiho Pharmaceutical Co Ltd | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 |
| CN117599061A (zh) * | 2016-11-17 | 2024-02-27 | 得克萨斯州大学系统董事会 | 具有针对携带egfr或her2外显子20突变之癌细胞的抗肿瘤活性的化合物 |
| CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
| FR3068971B1 (fr) * | 2017-07-12 | 2019-08-30 | Protneteomix | Acides 5-{4-allyl-5-[2-(4-alcoxyphenyl)quinolein-4-yl]-4h-1,2,4-triazole-3-ylsulphanylmethyl}furan-2-carboxyliques dans le traitement du cancer |
| FI3677266T3 (fi) * | 2017-09-01 | 2024-03-22 | Taiho Pharmaceutical Co Ltd | Eksoni 18- ja/tai eksoni 21 -egfr-mutantille selektiivinen inhibiittori |
| FI3902548T3 (fi) * | 2018-12-28 | 2025-07-17 | Taiho Pharmaceutical Co Ltd | Hoitoresistentin L718- ja/tai L792-mutaation omaavan EGFR:n inhibiittori käytettäväksi syövän hoitamisessa |
| MA55380A (fr) | 2019-03-19 | 2022-01-26 | B2Sbio Inc | Dérivé hétéroaryle, son procédé de production et composition pharmaceutique le comprenant en tant que constituant efficace |
| US12157730B2 (en) | 2019-03-19 | 2024-12-03 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| WO2021057796A1 (zh) * | 2019-09-29 | 2021-04-01 | 深圳市塔吉瑞生物医药有限公司 | 取代的稠合三环衍生物及其组合物及用途 |
| WO2021127456A1 (en) | 2019-12-19 | 2021-06-24 | Rain Therapeutics Inc. | Methods of inhibiting epidermal growth factor receptor proteins |
| CN113861195B (zh) * | 2020-06-30 | 2022-11-18 | 上海和誉生物医药科技有限公司 | 一种多稠环egfr抑制剂及其制备方法和应用 |
| CN116096372B (zh) * | 2020-07-09 | 2024-09-03 | 上海和誉生物医药科技有限公司 | 一种egfr抑制剂、其制备方法和在药学上的应用 |
| WO2022055895A1 (en) * | 2020-09-08 | 2022-03-17 | Cullinan Pearl Corp. | Treatment regimens for exon-20 insertion mutant egfr cancers |
| WO2022121967A1 (zh) * | 2020-12-09 | 2022-06-16 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| BR112023021111A2 (pt) | 2021-04-13 | 2023-12-19 | Nuvalent Inc | Composto, composição farmacêutica, método de tratamento de câncer, método para inibir seletivamente her2, método de regulação de um nível de her2, método para aumentar um nível de her2, método de diminuição da fosforilação de her2 |
| EP4355330A1 (en) | 2021-06-15 | 2024-04-24 | Genentech, Inc. | Egfr inhibitor and perk activator in combination therapy and their use for treating cancer |
| CN115707704B (zh) * | 2021-08-20 | 2024-09-13 | 广东医诺维申生物技术有限公司 | 氘代稠合三环类化合物及其组合物和用途 |
| WO2024121805A1 (en) | 2022-12-08 | 2024-06-13 | Assia Chemical Industries Ltd. | Solid state forms of zipalertinib and process for preparation thereof |
| CN115785107B (zh) * | 2022-12-15 | 2024-11-12 | 南京雷正医药科技有限公司 | 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途 |
| TW202502767A (zh) * | 2023-05-31 | 2025-01-16 | 日商大鵬藥品工業股份有限公司 | 喹啉取代化合物之結晶 |
| WO2025141465A1 (en) | 2023-12-27 | 2025-07-03 | Assia Chemical Industries Ltd. | Solid state forms of zipalertinib hydrochloride and process for preparation thereof |
| WO2025167588A1 (zh) * | 2024-02-05 | 2025-08-14 | 苏州科睿思制药有限公司 | Zipalertinib的晶型及其制备方法和用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW440562B (en) * | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
| KR20070113295A (ko) | 2005-03-17 | 2007-11-28 | 노파르티스 아게 | 티로신/트레오닌 키나제 억제제, 특히 ｂ-ｒａｆ 키나제억제제로서의ｎ-[3-(1-아미노-5,6,7,8-테트라히드로-2,4,4ｂ-트리아자플루오렌-9-일)-페닐]벤즈아미드 |
| MY152972A (en) | 2009-07-10 | 2014-12-15 | Taiho Pharmaceutical Co Ltd | Azabicyclo compound and salt thereof |
| US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| EP2662357B1 (en) * | 2011-01-07 | 2016-08-03 | Taiho Pharmaceutical Co., Ltd. | Bicyclic compounds or salts thereof for use in the treatment of cancer |
| JP5878178B2 (ja) * | 2011-09-30 | 2016-03-08 | 大鵬薬品工業株式会社 | １，２，４−トリアジン−６−カルボキサミド誘導体 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| WO2013118817A1 (ja) * | 2012-02-07 | 2013-08-15 | 大鵬薬品工業株式会社 | キノリルピロロピリミジン化合物又はその塩 |
| CN104136438B (zh) * | 2012-02-23 | 2016-04-06 | 大鹏药品工业株式会社 | 喹啉基吡咯并嘧啶基稠环化合物或其盐 |
| AU2014219754B2 (en) * | 2013-02-22 | 2016-05-05 | Taiho Pharmaceutical Co., Ltd. | Method for producing tricyclic compound, and tricyclic compound capable of being produced by said production method |
| TWI603971B (zh) * | 2013-08-22 | 2017-11-01 | Taiho Pharmaceutical Co Ltd | Novel quinoline substituted compounds |
-
2014
- 2014-08-22 TW TW103129036A patent/TWI603971B/zh active
- 2014-08-22 JP JP2015532903A patent/JP6161705B2/ja active Active
- 2014-08-22 US US14/911,093 patent/US9650386B2/en active Active
- 2014-08-22 CN CN201480058192.XA patent/CN105683195B/zh active Active
- 2014-08-22 MY MYPI2016700465A patent/MY182891A/en unknown
- 2014-08-22 HU HUE14837210A patent/HUE034807T2/en unknown
- 2014-08-22 SG SG11201600759XA patent/SG11201600759XA/en unknown
- 2014-08-22 PL PL14837210T patent/PL3037424T3/pl unknown
- 2014-08-22 DK DK14837210.5T patent/DK3037424T3/en active
- 2014-08-22 NO NO14837210A patent/NO3037424T3/no unknown
- 2014-08-22 AU AU2014309788A patent/AU2014309788B2/en active Active
- 2014-08-22 KR KR1020167007071A patent/KR101906688B1/ko active Active
- 2014-08-22 MX MX2016002125A patent/MX370808B/es active IP Right Grant
- 2014-08-22 BR BR112016003247-0A patent/BR112016003247B1/pt active IP Right Grant
- 2014-08-22 ES ES14837210.5T patent/ES2656712T3/es active Active
- 2014-08-22 RU RU2016110096A patent/RU2689158C2/ru active
- 2014-08-22 EP EP14837210.5A patent/EP3037424B1/en active Active
- 2014-08-22 CA CA2922077A patent/CA2922077C/en active Active
- 2014-08-22 PT PT148372105T patent/PT3037424T/pt unknown
- 2014-08-22 WO PCT/JP2014/071951 patent/WO2015025936A1/ja not_active Ceased
-
2016
- 2016-02-02 PH PH12016500225A patent/PH12016500225A1/en unknown
- 2016-12-19 US US15/382,883 patent/US9758526B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2656712T3 (es) | Novedoso compuesto sustituido con quinolina | |
| ES2582315T3 (es) | Derivado de ftalazinona-cetona, método de preparación de la misma y uso farmacéutico de la misma | |
| ES2942743T3 (es) | Tetrahidropiranil-amino-pirrolopirimidinona para usar en el tratamiento de trastornos mediados por BTK | |
| US10323037B2 (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| ES2955132T3 (es) | Compuestos heterocíclicos sustituidos con amina como inhibidores de EHMT2 y métodos de uso de los mismos | |
| TW202334137A (zh) | Ｐｉ３ｋ抑制劑及治療癌症之方法 | |
| ES2905981T3 (es) | Compuestos y composiciones como inhibidores de los receptores de tipo Toll endosomales | |
| ES2724929T3 (es) | Fármaco antitumoral para la administración intermitente de un inhibidor de FGFR | |
| ES2799520T3 (es) | Compuestos de pirazolo[3,4-d]pirimidina o sales de los mismos | |
| ES2621220T3 (es) | Derivados macrocíclicos para el tratamiento de enfermedades proliferativas | |
| ES2779225T3 (es) | Reactivos de merilformilo sustituido y procedimiento de uso de los mismos para modificar propiedades fisicoquímicas y/o farmacocinéticas de compuestos | |
| US20220227738A1 (en) | Kras g12c inhibitors and uses thereof | |
| ES2763274T3 (es) | Carboxamidas de tienopirazina como inhibidores de la proteasa específica de la ubiquitina | |
| BR112014018165B1 (pt) | compostos de indolizina, seu processo de preparação, composições farmacêuticas, seus usos e sal de cloridrato | |
| ES2899694T3 (es) | Compuestos novedosos, su síntesis y sus usos | |
| JP2018525394A (ja) | Ｉｒａｋ４阻害剤、及びその応用 | |
| TW202345836A (zh) | 可用作ＮＬＲＰ３衍生物之吡啶并－〔３，４－ｄ〕噠嗪胺衍生物 | |
| ES3035460T3 (en) | Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof | |
| US20250059183A1 (en) | Pyridine[4,3-d]pyrimidine compound as tlr7/8 agonist | |
| ES2751642T3 (es) | Compuestos inhibidores de bromodominios y composición farmacéutica que los comprende para prevenir o tratar un cáncer | |
| BR112021000101A2 (pt) | Derivados de tirosina amida como inibidores da rho-quinase, composição farmacêutica, dispositivo, combinação e uso | |
| WO2022127755A1 (en) | Compounds as casein kinase inhibitors | |
| US20240294550A1 (en) | 8-oxa-3-azabicyclo[3.2.1]octane compounds or salt thereof, and preparation method and use thereof | |
| WO2012007619A1 (es) | Proceso de obtención de derivados solubles en agua de 20(s)camptotecina como agentes antitumorales | |
| CA2909578C (en) | Furanone compounds as kinase inhibitors |